About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Erlotinib As Effective As Chemotherapy In Difficult Cancers

by Gopalan on February 27, 2011 at 8:48 AM
Font : A-A+

 Erlotinib As Effective As Chemotherapy In Difficult Cancers

Cancer drug erlotinib could be as effective as chemotherapy and is perhaps better tolerated in treatment of difficult cancers - particularly in cases where a patient's cancer has progressed quickly after treatment with first-line therapy.

The results of a new phase III trial have been reported at the European Multidisciplinary Conference in Thoracic Oncology (EMCTO), Lugano, Switzerland.

Advertisement

Presenting the findings of the international TITAN study at the conference, Dr Tudor Ciuleanu from the Institute of Oncology Ion Chiricuta said, "The TITAN study is the first trial to evaluate whether erlotinib has comparable efficacy to chemotherapy for non-small cell lung cancer patients in general."

The study included only patients whose disease had progressed under first-line chemotherapy. In the clinic, around 30-40% of patients with lung cancer will see no benefit from first-line therapy and their disease will rapidly progress.
Advertisement

"These patients have an extremely poor prognosis and few treatment options. An effective alternative to chemotherapy is therefore very important, since chemo-related side-effects can result in further physical deterioration in patients who are already very sick," Dr Ciuleanu said.

Historically, data have shown that erlotinib was more tolerable than chemotherapy, but many physicians had assumed that erlotinib would not be as effective in this difficult-to-treat patient population compared to chemotherapy.

The open-label study included 424 patients whose lung cancer had progressed rapidly after treatment with first-line chemotherapy. Of these, 203 were treated with erlotinib, and 221 received chemotherapy with either docetaxel or pemetrexed.

No difference in overall survival was seen between the two groups, the researchers reported. Nor was there any significant difference in progression-free survival time.

"TITAN is important because it confirms that erlotinib has comparable efficacy to chemotherapy with better tolerability, even in this population of patients with poor prognosis," Dr Ciuleanu said. "The study included a broad, unselected population, showing that patients can benefit from erlotinib regardless of their EGFR mutation status. Erlotinib therefore gives doctors an effective alternative to chemotherapy after disease progression, without chemo-related side-effects."

Serious treatment-related adverse events were seen in only 1% of patients treated with erlotinib, the researchers said, compared to 6.6% of those in the chemotherapy arm of the study.

"The likelihood of side-effects is a serious consideration for patients who are already physically unwell due to the advanced stage of their disease," Dr Ciuleanu said. "The importance of this finding is that when safety data are considered they show that the benefits associated with erlotinib can be achieved with better tolerability than chemotherapy."

Commenting on the study, which he was not involved in, Professor Jean-Paul Sculier from Institut Jules Bordet, Belgium, noted that there are currently three drugs specifically registered for second-line single-agent treatment in advanced non-small cell lung cancer, all of which have the same impact on survival: erlotinib, pemetrexed (restricted to non-squamous histologies) and docetaxel.

"Docetaxel is no longer protected by patent, meaning it is cheaper and generics are available," he noted. "A potential advantage of erlotinib is administration in a targeted way for tumors with activating EGFR mutations, however more data are needed before the drug can be recommended with a good level of evidence in that indication."



Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Diet and Oral Health: The Sugary Connection May Become Sour
World AIDS Day 2022 - Equalize!
Test Your Knowledge on Sugar Intake and Oral Health
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Chronic Lymphocytic Leukemia Hodgkins Lymphoma Non-Hodgkins Lymphoma Chemotherapy Chemotherapy Drugs Cancer Peritoneal Cancer Rhabdomyosarcoma Male Breast Cancer Tumor Lysis Syndrome 

Most Popular on Medindia

Vent Forte (Theophylline) Iron Intake Calculator Diaphragmatic Hernia Find a Doctor Accident and Trauma Care Drug Interaction Checker Drug - Food Interactions Blood - Sugar Chart Blood Donation - Recipients Turmeric Powder - Health Benefits, Uses & Side Effects
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Erlotinib As Effective As Chemotherapy In Difficult Cancers Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests